Natural Products

Preliminary Pre-Clinical Evaluation of a Molecule With Anti-Seizure Effects

BICS01 Epilepsy ASD molecule

Despite the availability of around 30 anti-seizure drugs, drug-resistant epilepsy remains a significant clinical and societal burden. We report the first promising result of a new candidate BICS01.

Planegg / Martinsried (Germany) – January 7, 2022 – Bicoll, an expert in synthesizing new and relevant small molecules as starting points for accelerated drug development, worked together with its partners at the University College London, FutureNeuro, and Royal College of Surgeons to publish data for a promising anti-seizure drug candidate BICS01 in Frontiers in Neurology.

Read more

Bio International Convention 2020

June, 8-11, 2020 – Bicoll exhibits under the roof of German Pavilion at Bio International Convention 2020 in San Diego. Bicoll owns small molecule, property-based isolation technologies to identify beneficial compounds (Bifrac N™ and Bipreselect™). These technologies turn plant extracts …

Read more

Natural based medicinal chemistry

Medicinal Chemistry & Synthesis: Bicoll seamlessly guides your synthesis and lead optimization projects through drug discovery and development with intensive understanding of structure-activity relationships, capability in biological data
interpretation, solid knowledge of intellectual property and patent aspects. Reliable and fast reporting …

Read more

Bicoll at 19. CEO & CFO meeting in Dresden

Dresden, December 6-7, 2017 – Bicoll CEO has participated in 19. CEO & CFO meeting in Dresden, organized by Bio Deutschland e.V. During the conference he has shortly presented the company as well as the last achievements of 2017. It …

Read more

New Bicoll homepage

Modern design and navigation improve the customer experience Planegg / Martinsried (Germany) – December, 11th, 2017 – Today, Bicoll Group has launched a newly designed and now, mobile optimized, company website at www.bicoll-group.com. In addition to our technology and products, …

Read more

Bicoll project at BIOTECHNICA, Hannover

Project forum Biotechnology, BIOTECHNICA, Hall 9, Expo Hannover. Dr. Kai Lamottke presented the BMBF project OLNORME “Deorphanising a Nuclear Receptor: Ligandenfindung mit pflanzlichen Naturstoffen”.

Foundation of Bicoll GmbH, Munich / Germany

Munich, Germany – December 1, 2000 – Bicoll GmbH has been founded in Munich, Germany, one of Europe’s most interesting biotech “hotspots”. Bicoll’s mission is to accelerate the developing process of new drug candidates. The growing biotechnology company provides an …

Read more

Join us at Biotechgate Partnering February 7th - 11thBiotechgate Partnering
+ +